Explore our full content library.
Found 7 results in 1ms
Found 7 results in 1ms
Feb 12, 2026
Lonza vs WuXi Biologics: BIOSECURE Act & U.S. Manufacturing Strategy
Partner Interview
Lonza Group•CH•Large CapCharles River Laboratories InternationalWuXi BiologicsCatalentThermo Fisher ScientificDanaherSwitching CostsMission Critical Products & ServicesOEMs w/ Installed BaseSerial AcquirerHealth CareSep 19, 2025
AGC Biologics & Western vs Chinese CDMOs
Partner Interview
AGC BiologicsWuXi BiologicsBayerLonza GroupThermo Fisher ScientificSartorius Stedim BiotechMerckPfizerCatalentSwitching CostsMission Critical Products & ServicesOEMs w/ Installed BaseHealth CareJul 30, 2025
Aldevron: mRNA, Plasmids and Synthetic DNA
Jan 20, 2025
Lonza: CDMO Market Capacity
Partner Interview
Lonza Group•CH•Large CapCatalentSartorius Stedim BiotechAbbVieAvid BioservicesDanaherThermo Fisher ScientificCharles River Laboratories InternationalSwitching CostsOEMs w/ Installed BaseMission Critical Products & ServicesSerial AcquirerHealth CareJan 14, 2025
Danaher vs Thermo Fisher: Plasmid Manufacturing & Gene Therapy Positioning
Dec 16, 2024
Danaher: Aldevron & DNA Plasmid Manufacturing
Oct 6, 2024
Lifecore Biomedical: Customer Mix, Switching Cost & Power in the CDMO Value Chain
Partner Interview
Landec•US•Small CapNovo NordiskLonza GroupCatalentHealth CareYou've reached the end